sabato, 25 marzo 2023
7 Gennaio 2019

Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry

This guidance provides recommendations to applicants on endpoints for cancer clinical trials submitted to the Food and Drug Administration (FDA) to support effectiveness claims in new drug applications (NDAs), biologics license applications (BLAs), or supplemental applications. It also provides background information and discusses general regulatory principles. The endpoints discussed in this guidance are for drugs to treat patients with an existing cancer … (leggi tutto)